Catalyst Pharmaceuticals Competitors and Similar CompaniesClear all
Catalyst Pharmaceuticals's competitors and similar companies include Omeros and Alnylam.
 Catalyst Pharmaceuticals Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. |  Omeros Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers. |  Alnylam Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments. | |
Founding Date | Founding Date 2002 | Founding Date 1994 | Founding Date 2002 |
Type | Type Public | Type Public | Type Public |
Tags | |||
Locations | Locations Coral Gables, US HQ | Locations Seattle, US HQ | |
Employees | Employees 7649% increase | Employees 1968% decrease | Employees 1,32324% increase |
Valuation ($) | Valuation ($) 2.6 b | Valuation ($) 248.6 m | Valuation ($) 36.5 b |
Financial | |||
Revenue (est.) | Revenue (est.) $589m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $3.7b (FY, 2025) |
Cost of goods | Cost of goods $87.3m (FY, 2025) | Cost of goods N/A | Cost of goods $677.2m (FY, 2025) |
Gross profit | Gross profit $501.7m (FY, 2025) | Gross profit N/A | Gross profit $3b (FY, 2025) |
Net income | Net income $214.3m (FY, 2025) | Net income ($3.4m) (FY, 2025) | Net income $313.7m (FY, 2025) |
Funding | |||
Total funding raised | Total funding raised N/A | Total funding raised $ 354.8m | Total funding raised $ 1.5b |
For sources of this data, please see the company profile
View Company Profiles
Omeros
HQ
Seattle, US
Employees
196↓ 8% decrease
Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers.
View companyAlnylam
HQ
Cambridge, US
Employees
1,323↑ 24% increase
Alnylam is a biopharmaceutical company that develops ribonucleic acid interference (RNAi) therapeutics for hepatic porphyria, primary hyperoxaluria type 1 (PH1), cardiovascular, and polyneuropathy treatments.
View company